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adness in Heart Failure
hat Is a Clinician to Do?*
arah J. Goodlin, MD
alt Lake City, Utah
epression or depressive symptoms are common in the
eneral population, and more common in heart failure (HF)
atients, ranging from about 20% based on structured
sychiatric interview to almost 40% based on screening tools
1). Clinicians caring for HF patients may not have any
articular expertise in the management of depression; thus,
atients’ depressive symptoms are at best challenging. In
ontrast to many aspects of HF care, there is nearly no
vidence base to clarify a course of care for the sad, listless,
r unenergetic HF patient.
See page 692
The SADHART-CHF (Sertraline Against Depression
nd Heart Disease in Chronic Heart Failure) trial reported
n this issue of the Journal is the first randomized, controlled
tudy to attempt to provide guidance regarding medication
anagement of depression in HF, yet it leaves many
uestions unanswered (2). The SADHART-CHF trial is
n almost 5-year double-blind, randomized trial of sertra-
ine versus placebo in patients with depression and HF due
o left ventricular systolic dysfunction. The study was
imited by investigator titration of medication, achieving
enerally low doses of sertraline (mean 65 mg/day). Sertra-
ine efficacy originally was established based on a mean dose
f 145 mg/day. In general, clinical care doses of 200 mg/day
f sertraline are common.
As the authors note, the Hamilton Depression Rating
cale scores of subjects may also have been lower than those
f patients who typically respond to antidepressants. The
ADHART-CHF trial tells us that discontinuation or
dverse event rates were a bit higher with low-dose sertra-
ine than with placebo, that low to moderate doses of
ertraline are not associated with increased HF decompen-
ation or death, and that supportive nursing interventions
eem as effective as low-dose sertraline for HF patients with
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cientific CARE.oderate depressive symptoms. Further research is needed
o tell us whether higher doses of sertraline or other
ntidepressants are both safe and effective.
We know from many studies that depressive symptoms
re more common in patients with a worse HF status.
tudies of “depression” in HF unfortunately commonly use
ools created to screen for depression in the general popu-
ation, such as the Beck Depression Inventory. These tools
o not correlate well with newer Diagnostic and Statistical
anual-Fourth Edition definitions of depression and in-
lude somatic symptoms that likely overlap with HF symp-
oms. A higher threshold for a positive screen on such tools
s indicated in patients with chronic illness, and these tools
ave not been critically studied in HF per se. A positive
creen on tools for depression does not a “depression”
iagnosis make. How to recognize depression in HF pa-
ients is a long discussion, but newer tools, such as the
atient Health Questionnaire, a 9-item depression screen,
hat are based on Diagnostic and Statistical Manual-Fourth
dition criteria (3) or tools developed specifically for med-
cally ill patients, such as the Geriatric Depression Scale (4),
ight help. Importantly though, screening for depression
lone is not likely to benefit patients. Coordinated care that
ncludes regular follow-up and support or counseling and,
hen medications are needed, up-titration or changes in
rescription are essential.
Because HF includes neurohormonal activation, and we
peculate that elevated levels of norepinephrine might be
ssociated with symptoms of depression and anxiety in HF
atients, a first step in managing depressive symptoms
hould be to aggressively treat the HF. Close to normal
olume status should be achieved. For patients with systolic
ysfunction, angiotensin-converting enzyme inhibitor and
eta-blocker therapy should be maximized. Sleep-disordered
reathing, in itself associated with elevated norepinephrine and
pinephrine and with depression and anxiety, should be iden-
ified and treated. Although its effect on depression was not
pecifically evaluated in HF patients, exercise has been dem-
nstrated to improve depression in general populations; thus,
n exercise program should be initiated in any HF patient with
epressive symptoms. Thigh muscle strengthening may have
he added benefit of decreasing fatigue and dyspnea (5).
What about medication management of depression? We
now very little in HF patients. Tricyclic antidepressants fell
ut of vogue when selective serotonin reuptake inhibitors
ecame available, but both classes of drugs have potential
enefits and adverse effects in HF patients. Tricyclic anti-
epressants have a quinidine-like effect causing QTc pro-
ongation and have variable anticholinergic effects, the most
ignificant of which may be orthostatic hypotension and dry
outh. (The latter might increase oral intake of fluids.) The
elective serotonin reuptake inhibitors also cause orthostatic
ypotension and, importantly in patients with mild to moder-
te renal impairment, can cause hyponatremia and fluid reten-
ion via antidiuretic hormone actions. All patients with renal
i
r
s
p
k
i
p
n
R
P
S
R
1
2
3
4
5
701JACC Vol. 56, No. 9, 2010 Goodlin
August 24, 2010:700–1 Sadness in HFmpairment taking selective serotonin reuptake inhibitors need
egular and ongoing assessment of serum sodium and volume
tatus. Clinicians should become familiar with several antide-
ressants with different side effect profiles (clinicians should
now one “sedating” or calming medication and one “activat-
ng” or stimulating medication at least). Therapy for individual
atients should be titrated to improved symptoms.
Clearly further study of depression in HF patients is
eeded. What should the clinician do now?
• Aggressively treat HF, with particular attention to
modulating neurohormonal activation (use beta-
blockers and angiotensin-converting enzyme inhibi-
tors at maximally tolerated doses).
• Identify and treat sleep-disordered breathing.
• Initiate an exercise program with special attention to
thigh muscle strengthening.
• Provide nurse or other clinician supportive interventions
and counseling to facilitate HF management and coping.
• Consider pharmacologic treatment of depression,
monitoring response and side effects. Either up-titrate
to an effective dose or change medications if no
response or if side effects limit dosing. Connect the Kpatient with clinicians more expert in psychiatric
medical care when initial therapy is unsuccessful.
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